Search research articles
Contact Us
Filters
Showing results (1-10 of 652) with videos related to
Page
of 66
Sort By:
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie
|
June 29, 2001
Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada
R Panaccione,
Crohn'S & Colitis 360
|
February 13, 2023
The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference Biologics
Remo Panaccione
Journal of the Canadian Association of Gastroenterology
|
February 24, 2025
What is first-line and what is second-line therapy in adult patients with moderate to severe Crohn's disease?
Remo Panaccione
Microbial Biotechnology
|
January 13, 2023
Derivation of the multiply-branched ergot alkaloid pathway of fungi
Daniel G Panaccione
FEMS Microbiology Letters
|
August 23, 2005
Origins and significance of ergot alkaloid diversity in fungi
Daniel G Panaccione
Trends in Microbiology
|
April 1, 1993
The fungal genus Cochliobolus and toxin-mediated plant disease
D G Panaccione
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
July 10, 2008
Anti-adhesion molecule strategies for Crohn disease
Yvette Leung, Remo Panaccione
Current Opinion in Gastroenterology
|
July 16, 2008
Biologic therapy in Crohn's disease: state of the art
Jennifer Jones, Remo Panaccione
Therapeutic Advances in Gastroenterology
|
December 25, 2010
Anti-adhesion molecule therapy for inflammatory bowel disease
Subrata Ghosh, Remo Panaccione
Gastroenterology Clinics of North America
|
August 12, 2014
Update on ustekinumab for the treatment of Crohn's disease
Yvette Leung, Remo Panaccione
Page
of 66
Search research articles
Search
Showing results (1-10 of 652) with videos related to
Sort By:
Page
of 66
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie
|
June 29, 2001
Infliximab for the treatment of Crohn's disease: review and indications for clinical use in Canada
R Panaccione,
Crohn'S & Colitis 360
|
February 13, 2023
The Great Debate With IBD Biosimilars: Con: Biosimilars Should Not Be Routinely Used as a First Line Biologic and Not Switched From Reference Biologics
Remo Panaccione
Journal of the Canadian Association of Gastroenterology
|
February 24, 2025
What is first-line and what is second-line therapy in adult patients with moderate to severe Crohn's disease?
Remo Panaccione
Microbial Biotechnology
|
January 13, 2023
Derivation of the multiply-branched ergot alkaloid pathway of fungi
Daniel G Panaccione
FEMS Microbiology Letters
|
August 23, 2005
Origins and significance of ergot alkaloid diversity in fungi
Daniel G Panaccione
Trends in Microbiology
|
April 1, 1993
The fungal genus Cochliobolus and toxin-mediated plant disease
D G Panaccione
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|
July 10, 2008
Anti-adhesion molecule strategies for Crohn disease
Yvette Leung, Remo Panaccione
Current Opinion in Gastroenterology
|
July 16, 2008
Biologic therapy in Crohn's disease: state of the art
Jennifer Jones, Remo Panaccione
Therapeutic Advances in Gastroenterology
|
December 25, 2010
Anti-adhesion molecule therapy for inflammatory bowel disease
Subrata Ghosh, Remo Panaccione
Gastroenterology Clinics of North America
|
August 12, 2014
Update on ustekinumab for the treatment of Crohn's disease
Yvette Leung, Remo Panaccione
Page
of 66